Status report
Get it in writing
The official USPTO status record for CLARITY, serial 99668484, as a dated PDF. One price, one document, delivered in about a minute.
INSTANT DELIVERY
Trademark Status Report
$7.99
The USPTO's own status record for this mark, on one dated page.
- Current status with a plain-English verdict
- Owner, classes, filing basis, and every key date
- The mark as it appears on the federal record
- Every prosecution event, filing to today
- Source-cited with the exact retrieval date
Built from the USPTO's TSDR record. Assignment chain of title and TTAB proceeding files sit in separate USPTO systems and are not included.
Preview
◆ TRADEMARKCHECKER.AITRADEMARK STATUS REPORT
CLARITYSerial 99668484 · Principal Register
Pending · Published for Opposition
Owner: Axsome Therapeutics, Inc.
Class 005 - Pharmaceuticals
Filed Feb 24, 2026
The record shows a live, pending application for the mark CLARITY owned by Axsome Therapeutics, Inc., a Delaware corporation, and it is being pursued on the Principal Register. The filing covers Class 005 pharmaceutical preparations specifically for treating Major Depressive Disorder and Excessive Daytime Sleepiness, so a later use of “Clarity” in any drug or therapy context for those conditions would be the closest area of concern. The record does not give Axsome control over every possible use of the word “Clarity” in unrelated fields. The most recent meaningful event is the issuance of a Notice of Allowance on August 11 2026, which now requires the applicant to file a Statement of Use or request an extension within six months. The prosecution history shows no oppositions, cancellations or court actions, so the supplied history shows no visible enforcement activity. I'd treat this as a meaningful concern if you plan a similar name in the same therapeutic space.
Full event history, owner details, and verdict inside.
The way I'd use it, honestly, is as the thing you attach when a bank, a marketplace, or a co-founder asks "are we clear on the name". It answers in one page.